Literature DB >> 19483736

Targeted therapies: Goldie-Coldman and bevacizumab beyond disease progression.

Bruce J Giantonio1.   

Abstract

Targeted therapies offer new hope in overcoming the challenges encountered with conventional chemotherapy. However, little is known about the precise mechanisms that cause resistance. These issues are discussed in light of data from the BRiTE study, which indicate that the antiangiogenic effects of bevacizumab might persist despite the development of resistance to first-line chemotherapy.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19483736     DOI： 10.1038/nrclinonc.2009.66

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


  6 in total

Review 1.  Resistance to chemotherapy in cancer: a complex and integrated cellular response.

Authors:  Howard R Mellor; Richard Callaghan
Journal:  Pharmacology       Date:  2008-02-07       Impact factor: 2.547

Review 2.  Antiangiogenic therapy for cancer: current and emerging concepts.

Authors:  Rakesh K Jain
Journal:  Oncology (Williston Park)       Date:  2005-04       Impact factor: 2.990

3.  Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE).

Authors:  Axel Grothey; Mary M Sugrue; David M Purdie; Wei Dong; Daniel Sargent; Eric Hedrick; Mark Kozloff
Journal:  J Clin Oncol       Date:  2008-10-14       Impact factor: 44.544

4.  A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate.

Authors:  J H Goldie; A J Coldman
Journal:  Cancer Treat Rep       Date:  1979 Nov-Dec

Review 5.  Vascular endothelial growth factor: biology and therapeutic applications.

Authors:  Quoc T Ho; Calvin J Kuo
Journal:  Int J Biochem Cell Biol       Date:  2007-04-22       Impact factor: 5.085

Review 6.  Modes of resistance to anti-angiogenic therapy.

Authors:  Gabriele Bergers; Douglas Hanahan
Journal:  Nat Rev Cancer       Date:  2008-08       Impact factor: 60.716
  6 in total
  7 in total

Review 1.  Anti-angiogenic agents in metastatic colorectal cancer.

Authors:  Bhavana Konda; Helen Shum; Lakshmi Rajdev
Journal:  World J Gastrointest Oncol       Date:  2015-07-15

Review 2.  The role of vascular endothelial growth factor inhibitors in the treatment of epithelial ovarian cancer.

Authors:  Alexander D Murphy; Robert D Morgan; Andrew R Clamp; Gordon C Jayson
Journal:  Br J Cancer       Date:  2021-10-29       Impact factor: 9.075

3.  Anti-EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacy.

Authors:  Leisa Johnson; Mahrukh Huseni; Tanya Smyczek; Anthony Lima; Stacey Yeung; Jason H Cheng; Rafael Molina; David Kan; Ann De Mazière; Judith Klumperman; Ian Kasman; Yin Zhang; Mark S Dennis; Jeffrey Eastham-Anderson; Adrian M Jubb; Olivia Hwang; Rupal Desai; Maike Schmidt; Michelle A Nannini; Kai H Barck; Richard A D Carano; William F Forrest; Qinghua Song; Daniel S Chen; Louie Naumovski; Mallika Singh; Weilan Ye; Priti S Hegde
Journal:  J Clin Invest       Date:  2013-08-15       Impact factor: 14.808

4.  Changes in expression levels of ERCC1, DPYD, and VEGFA mRNA after first-line chemotherapy of metastatic colorectal cancer: results of a multicenter study.

Authors:  Hideo Baba; Yoshifumi Baba; Shinji Uemoto; Kazuhiro Yoshida; Akio Saiura; Masayuki Watanabe; Yoshihiko Maehara; Eiji Oki; Yasuharu Ikeda; Hiroyuki Matsuda; Masakazu Yamamoto; Mitsuo Shimada; Akinobu Taketomi; Michiaki Unno; Kenichi Sugihara; Yutaka Ogata; Susumu Eguchi; Seigo Kitano; Kazuo Shirouzu; Yasumitsu Saiki; Hiroshi Takamori; Masaki Mori; Toshihiko Hirata; Go Wakabayashi; Norihiro Kokudo
Journal:  Oncotarget       Date:  2015-10-20

Review 5.  Optimizing sequential treatment with anti-EGFR and VEGF mAb in metastatic colorectal cancer: current results and controversies.

Authors:  Datian Chen; Kaikai Gu; Huiyu Wang
Journal:  Cancer Manag Res       Date:  2019-02-19       Impact factor: 3.989

Review 6.  Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities.

Authors:  Xiufang Xu; Miaofeng Zhang; Faying Xu; Shaojie Jiang
Journal:  Mol Cancer       Date:  2020-11-24       Impact factor: 27.401

7.  The prognosis for patients with newly diagnosed glioblastoma receiving bevacizumab combination therapy: a meta-analysis.

Authors:  Ke-Li Liao; Song Huang; Yu-Peng Wu
Journal:  Onco Targets Ther       Date:  2018-06-19       Impact factor: 4.147
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.